IL225868B - A2a antagonists as enhancers of motor and mental activity - Google Patents

A2a antagonists as enhancers of motor and mental activity

Info

Publication number
IL225868B
IL225868B IL225868A IL22586813A IL225868B IL 225868 B IL225868 B IL 225868B IL 225868 A IL225868 A IL 225868A IL 22586813 A IL22586813 A IL 22586813A IL 225868 B IL225868 B IL 225868B
Authority
IL
Israel
Prior art keywords
cognition
antagonists
motor function
function enhancers
enhancers
Prior art date
Application number
IL225868A
Other languages
English (en)
Hebrew (he)
Other versions
IL225868A0 (en
Original Assignee
Biotie Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Inc filed Critical Biotie Therapies Inc
Publication of IL225868A0 publication Critical patent/IL225868A0/en
Publication of IL225868B publication Critical patent/IL225868B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL225868A 2010-11-05 2013-04-21 A2a antagonists as enhancers of motor and mental activity IL225868B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/055681 WO2012060844A1 (en) 2010-11-05 2010-11-05 A2a antagonists as cognition and motor function enhancers
PCT/US2011/059466 WO2012061787A1 (en) 2010-11-05 2011-11-04 A2a antagonists as cognition and motor function enhancers

Publications (2)

Publication Number Publication Date
IL225868A0 IL225868A0 (en) 2013-07-31
IL225868B true IL225868B (en) 2019-05-30

Family

ID=46024745

Family Applications (2)

Application Number Title Priority Date Filing Date
IL225868A IL225868B (en) 2010-11-05 2013-04-21 A2a antagonists as enhancers of motor and mental activity
IL266321A IL266321A (en) 2010-11-05 2019-04-29 A2a antagonists as enhancers of motor and mental activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL266321A IL266321A (en) 2010-11-05 2019-04-29 A2a antagonists as enhancers of motor and mental activity

Country Status (15)

Country Link
US (2) US20130317019A1 (enExample)
EP (1) EP2635256B1 (enExample)
JP (3) JP6315991B2 (enExample)
KR (2) KR102166229B1 (enExample)
CN (3) CN107281491A (enExample)
AU (3) AU2011323152A1 (enExample)
BR (1) BR112013011068A2 (enExample)
CA (1) CA2816834A1 (enExample)
EA (2) EA202091356A1 (enExample)
ES (1) ES2842968T3 (enExample)
HK (1) HK1245138A1 (enExample)
IL (2) IL225868B (enExample)
MX (2) MX382823B (enExample)
NZ (2) NZ609803A (enExample)
WO (2) WO2012060844A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6339758B2 (ja) * 2012-07-02 2018-06-06 国立研究開発法人国立長寿医療研究センター 軽度認知機能障害の有無の診断システム、認知機能検査用端末及び認知機能検査用プログラム
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
AU2016278846B2 (en) 2015-06-19 2021-08-05 Biotie Therapies, Inc. Controlled-release tozadenant formulations
EP4501406A3 (en) * 2016-04-19 2025-03-26 IntraBio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
US11246871B2 (en) 2016-07-15 2022-02-15 Northwestern University Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
CN115397425A (zh) * 2019-12-02 2022-11-25 希诺皮亚生物科学公司 使用曲匹地尔治疗认知障碍

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198753A1 (en) * 2002-01-28 2004-10-07 Hiroshi Kase Methods of treating patients suffering from movement disorders
EP1753760B1 (en) * 2004-05-24 2008-01-02 F.Hoffmann-La Roche Ag 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives

Also Published As

Publication number Publication date
HK1245138A1 (zh) 2018-08-24
MX382823B (es) 2025-03-13
KR20130143597A (ko) 2013-12-31
JP6315991B2 (ja) 2018-04-25
WO2012061787A1 (en) 2012-05-10
JP6611896B2 (ja) 2019-11-27
JP2019052163A (ja) 2019-04-04
EA202091356A1 (ru) 2020-12-30
AU2017201446A1 (en) 2017-03-23
WO2012060844A1 (en) 2012-05-10
CA2816834A1 (en) 2012-05-10
CN103429221A (zh) 2013-12-04
EP2635256A4 (en) 2014-05-21
US20130317019A1 (en) 2013-11-28
EA035900B1 (ru) 2020-08-28
JP2013541593A (ja) 2013-11-14
IL225868A0 (en) 2013-07-31
ES2842968T3 (es) 2021-07-15
BR112013011068A2 (pt) 2016-08-23
JP2017019829A (ja) 2017-01-26
NZ746118A (en) 2020-03-27
EP2635256B1 (en) 2020-10-21
NZ609803A (en) 2016-08-26
CN107281491A (zh) 2017-10-24
EA201390653A1 (ru) 2013-12-30
KR102166229B1 (ko) 2020-10-15
KR20190025734A (ko) 2019-03-11
AU2018286608B2 (en) 2020-07-30
CN109223799A (zh) 2019-01-18
EP2635256A1 (en) 2013-09-11
IL266321A (en) 2019-06-30
JP6444951B2 (ja) 2018-12-26
US20220125772A1 (en) 2022-04-28
AU2018286608A1 (en) 2019-01-24
KR101955045B1 (ko) 2019-03-06
MX2013005014A (es) 2014-01-31
AU2011323152A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
IL266321A (en) A2a antagonists as enhancers of motor and mental activity
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
PH12013500299A1 (en) Pyrrolopyrimidine compounds and uses thereof
IL222176B (en) Radioprotector compounds and methods
IL226651A (en) Converted compounds of furin and 7-diazaphorin
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
IL226422A0 (en) Disubstituted 1-benzylcycloalkylcarboxylic acids and their use
EP2612804A4 (en) INDUSTRIAL VEHICLE
LT2946791T (lt) Anti-cd277 antikūnai ir jų panaudojimas
GB201020574D0 (en) Assay assembly and methods
IL220812A0 (en) Compounds and methods
PT2531518T (pt) Compostos oligopeptídicos e suas utilizações
GB201003781D0 (en) Improvements in the control of vehicle emissions
AP2012006634A0 (en) Garmetn and brasserie accessory
EP2523560A4 (en) CONNECTIONS AND METHODS
EP2554438A4 (en) VEHICLE PIECE
ZA201207089B (en) Adenosine compounds and their use thereof
ZA201209237B (en) Furanyl compounds and the use thereof
GB201004450D0 (en) Compounds and methods relating thereto
TWM387825U (en) Vehicle handle structure
GB201014319D0 (en) Compounds and uses thereof
GB201019361D0 (en) Biosensor and uses thereof
GB201017844D0 (en) Trim component

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed